Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MIF | P14174 | 1/20 | 0.49 |
| ▸ | GLS | O94925 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | GPR119 | Q8TDV5 | 5/20 | 0.43 |
| ▸ | TP53 | P04637 | 3/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2194586 | 0.84 | FAAH (0.48) | ALDH1A1LMNAGPR119 | |
| SCHEMBL4710410 | 0.82 | GLS (0.52) | GLSMEN1ALDH1A1LMNATSHR | |
| SCHEMBL29910448 | 0.82 | GLS (0.52) | GLSMEN1ALDH1A1LMNATSHR | |
| SCHEMBL4709921 | 0.82 | GLS (0.52) | GLSALDH1A1TP53THRBMAPT | |
| SCHEMBL4837787 | 0.80 | GLS (0.54) | GLSMEN1ALDH1A1LMNATSHR | |
| SCHEMBL13236926 | 0.80 | GLS (0.54) | GLSALDH1A1LMNAKMT2ASMN1; SMN2 | |
| SCHEMBL30812262 | 0.80 | GPR119 (0.51) | GPR119 | |
| SCHEMBL24732680 | 0.79 | PRMT6 (0.54) | GLSALDH1A1TP53THRBMAPT | |
| SCHEMBL16855800 | 0.79 | GLS (0.53) | GLSMEN1ALDH1A1LMNATSHR | |
| SCHEMBL4147236 | 0.78 | SLC2A1 (0.56) | MEN1ALDH1A1KMT2AGPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110172230-A1 | UREA COMPOUND OR SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2011-07-14 | — | — | US | disclosed |
| EP-2065369-A1 | UREA COMPOUND OR SALT THEREOF | Astellas Pharma Inc. (JP) | 2009-06-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110172230-A1 | UREA COMPOUND OR SALT THEREOF | FAAH, FAAH2, UTS2R | MIF 2401/4885GLS 447/4885MEN1 4707/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.